"Translating Articular Biomarkers Into Diagnoses"

Condition(s) studied

Investigational drug(s) / intervention(s)

Collection of joint fluid or tissue sample: During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.

Study summary

Early diagnosis is a key factor in the prevention and management of rheumatic diseases. Rheumatic diseases are classically diagnosed based on criteria combining clinical, biological and radiological features. However, in up to 20% of the cases, diagnoses remain unstated and underlying rheumatic diseases unclassified, which might lead to delayed specific treatment and unfavourable clinical outcomes. In addition, conventional methods could lack sensitivity and specificity for early diagnosis. Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory\]. Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration, blood by venous puncture and tissue specimen by surgery. The investigators hypothesize that in challenging situations, novel biomarkers detected from synovial fluid or articular tissues using both conventional (e.g. histology, immunodetection, PCR) and innovative (e.g. Raman spectroscopy, nanospectroscopy) laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases.

Eligibility

Primary outcome measure(s)

• Tissues and biofluid spectra using surface-enhanced Raman spectroscopy — Inclusion
  Molecular signature of articular samples
• Protein expression using immunodetection techniques and RNA expression using PCR — Inclusion
  Cellular signature of articular samples

Trial sites (1)

More Assistance Publique - Hôpitaux de Paris trials in France